US 12,168,006 B2
Cancer therapy by degrading dual MEK signaling
Paul J. Hergenrother, Champaign, IL (US); Jessie Peh, Champaign, IL (US); and Matthew Boudreau, Newton, MA (US)
Assigned to The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed by The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed on Nov. 28, 2022, as Appl. No. 18/059,024.
Application 18/059,024 is a continuation of application No. 16/764,103, granted, now 11,510,919, previously published as PCT/US2018/061579, filed on Nov. 16, 2018.
Claims priority of provisional application 62/587,707, filed on Nov. 17, 2017.
Prior Publication US 2023/0158019 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/495 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/4523 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/495 (2013.01) [A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/4523 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 13 Claims
 
1. A composition in solid unit dosage form comprising:
(a) the compound PAC-1:

OG Complex Work Unit Chemistry
and
(b) at least one second active agent, wherein the at least one second active agent is an inhibitor of a mutant kinase, and the at least one second agent is osimertinib.